Antidote to drugs

1. At a Glance

• Spurious/counterfeit drugs — fake, relabelled, or expired medicines sold as genuine — pose a direct patient-safety threat, especially for time-sensitive drugs (cancer, ICU injections) [4].
• Regulated under the Drugs and Cosmetics Act, 1940, enforced by CDSCO (Central Drugs Standard Control Organisation) under the Ministry of Health & Family Welfare [3].
• UPSC relevance: tests governance/regulatory-body knowledge (CDSCO vs. state drug controllers), federal enforcement gaps, and public health administration (GS-II/III).

2. Why in the News

• A counterfeit medicine racket was busted in Bengaluru, Karnataka, after raids near Bidadi on 18 August 2026 uncovered fake and expired drugs — cancer drugs and ICU injections — at an unlicensed farmhouse unit with a label value of ₹5 crore [4].
• Drugs with altered expiry dates, repackaged as fresh or imported branded products, were sold at steep discounts to over 90 hospitals and clinics across Karnataka, via a Bengaluru pharmacy nexus [4].
• Karnataka formed a Special Investigation Team (SIT) to trace the wider distribution network; some accused arrested, one absconding abroad [4].

3. Background & Evolution

• Drugs and Cosmetics Act, 1940 and Rules, 1945 form the primary legal framework governing manufacture, sale, and distribution of drugs in India [3].
• CDSCO, under the Directorate General of Health Services, functions as India's National Regulatory Authority (NRA) for drugs [3].
• Government has undertaken risk-based inspections of drug manufacturing/testing units since December 2022; as of recent reporting, 905 units inspected, leading to 694 enforcement actions (Stop Production/Testing Orders, licence suspension/cancellation, warning letters, show-cause notices) [3].
• Prior major incidents: spurious anti-cancer/anti-diabetic drugs worth ₹6.6 crore seized in Kolkata in a joint CDSCO–West Bengal Drugs Control Directorate operation [1].

4. Core Static Facts

Item	Detail
Enabling law	Drugs and Cosmetics Act, 1940 & Rules, 1945 [3]
Regulator (Central)	CDSCO, under DGHS, Ministry of Health & Family Welfare [3]
Regulator (State)	State Drugs Controllers/Drug Control Departments (Karnataka in this case)
Definition — "spurious drug"	Manufactured under another drug's name, an imitation/substitute, or resembling another drug [3]
Penalty for spurious drugs	Imprisonment up to 3 years + fine [3]
Monitoring mechanism	CDSCO + state regulators sample drugs nationwide; failed samples published as monthly Drug Alerts on CDSCO website [3]
Recent case scale	₹5 crore label value; 90+ hospitals/clinics supplied; Bidadi, Karnataka [4]

5. Multi-Dimensional Analysis

Social

• Direct risk to patients receiving cancer therapy and ICU care — vulnerable, critically-ill populations bear the highest risk [4].
• Erodes public trust in healthcare supply chains, particularly for poorer patients dependent on discounted/generic drugs.

Legal / Constitutional

• Falls under Concurrent List dynamics — drug manufacturing/licensing is a state subject administratively, while CDSCO sets central standards, creating enforcement fragmentation [3].
• Existing penalty (max 3 years) has been criticised as inadequate deterrent relative to the ₹5-crore-scale racket uncovered [3][4].

Administrative / Governance

• Enforcement gap: an unlicensed farmhouse unit operated undetected, supplying 90+ institutions — indicates weak surveillance and supply-chain traceability [4].
• Highlights the need for track-and-trace/serialisation of drugs and stronger inter-state coordination (accused fled the country) [4].

Economic

• Counterfeit drugs distort the pharmaceutical market — genuine manufacturers undercut by illicit, discount-priced fake products.
• Country's status as "pharmacy of the world" (major generics exporter) makes domestic quality lapses reputationally costly.

Ethical

• Deliberate profiteering from life-saving, time-sensitive medicines represents a severe ethical breach amounting to public endangerment.

6. Recent Developments (last 12-18 months)

• 18 August 2026: Raids near Bidadi, Karnataka uncover fake/expired drugs at unlicensed farmhouse [4].
• 2026: Karnataka SIT formed to map full distribution network reaching 90+ hospitals/clinics [4].
• Arrests made; one suspect currently abroad and being tracked [4].
• Ongoing CDSCO risk-based inspection drive (initiated December 2022) continues, with cumulative unit inspections and actions reported [3].

7. Prelims Hooks

• Drugs and Cosmetics Act enacted in 1940; Rules framed in 1945 [3].
• CDSCO = Central Drugs Standard Control Organisation, India's National Regulatory Authority for drugs [3].
• CDSCO functions under the Directorate General of Health Services, Ministry of Health & Family Welfare [3].
• Punishment for manufacturing/selling spurious drugs: imprisonment up to 3 years with fine [3].
• CDSCO publishes monthly Drug Alerts listing drugs failing quality tests [3].
• Risk-based inspection drive of drug units began in December 2022 [3].
• Recent Bengaluru counterfeit racket: fake drugs traced to an unlicensed unit near Bidadi, Karnataka [4].
• Label value of the seized consignment: ₹5 crore [4].
• Fake/expired drugs supplied to 90+ hospitals and clinics across Karnataka [4].
• Karnataka government response: constitution of a Special Investigation Team (SIT) [4].
• Earlier precedent: ₹6.6 crore spurious anti-cancer/anti-diabetic drug seizure in Kolkata via CDSCO–West Bengal joint operation [1].

8. Why the Official "0.02% Spurious" Figure Is Not the Real Rate

• The official number counts only what inspectors happen to pick up
• In one year of testing, out of 47,012 samples, just 13 were spurious (about 0.02%) and 1,850 were NSQ — Not of Standard Quality, meaning the drug failed a quality test but there is no proof anyone meant to cheat — that is 3.16% [5].
• Inspectors draw most samples from licensed chemist shops and licensed factories.

• The Bidadi unit had no licence and sold straight to hospitals and clinics [4]. A unit like that is never on any sampling list, so it can never show up in the 0.02%.

• An independent global count found a far bigger problem

• WHO studied 48,000 medicine samples in 88 low- and middle-income countries. About 1 in 10 medical products was substandard or falsified [6].

• Countries spend roughly US$30.5 billion a year on such products [6].

• Exam trap: the two numbers do not measure the same thing

• WHO's 1-in-10 counts both substandard and falsified products [6].
• India's 0.02% counts only spurious (deliberate fakes) [5].
• If you must compare, compare WHO's figure with India's own NSQ rate of 3.16% [5] — not with 0.02%.

9. The Same Diagnosis Was Made in 2003 and Never Fixed

• The Mashelkar Committee (2003) named three faults that are still the faults today [7]
• Too few trained and skilled staff, at both the Centre and the states.
• Each state enforces the same rules in a different way.

• Weak drug control infrastructure at state and central level.

• Why staff shortage is the root, not a side issue

• CDSCO's sanctioned posts rose from 111 in 2008 to 492 by January 2021 [5].
• "Sanctioned" means posts allowed on paper — not posts actually filled.

• The Centre writes the standards, but the inspectors who visit factories work for the states. So a state with few inspectors simply does not look, and no central rule changes that.

• The problem is not only fakes from outside — the approval side has failed too

• Parliament's Standing Committee on Health, in its report on CDSCO tabled on 8 May 2012, found 31 new drugs approved between January 2008 and October 2010 without clinical trials on Indian patients [7].

• The same report said drug makers, CDSCO officials and medical experts had colluded to approve drugs in violation of the law [7].

• What should change: Health Ministry should report filled posts, not sanctioned posts

• Mashelkar's very first finding was personnel [7], so the honest measure of progress is how many inspector posts are filled and how many manufacturing units each inspector must cover.
• Today only the sanctioned figure is put out [5], which hides the gap.

10. QR Codes Did Not Cover Cancer Drugs When This Racket Ran

• India's track-and-trace rule started small
• A QR code or barcode on the pack became compulsory for the top 300 drug brands from 1 August 2023 [8].

• The code lets a buyer check where that exact pack came from.

• Anticancer drugs come in only later

• The mandate is being widened in phases: vaccines, narcotics and anticancer drugs by July 2027, and antimicrobials by July 2028 [8].

• The Bidadi raids happened in August 2026, and cancer drugs were among the fakes [4] — a full year before anticancer packs had to carry a code.

• Even a code only helps if somebody scans it

• A code printed on a carton can be photographed and printed again on a fake carton.

• It protects the patient only when the hospital scans it and checks it against the maker's database. No rule forces a hospital to scan before use.

• What should change: CDSCO should pull the anticancer date forward

• The July 2027 deadline for anticancer drugs [8] is set for the very category that this racket targeted [4].
• Cancer and ICU drugs are where a fake kills fastest, so they deserve the earliest date, not a later one.

11. The 90 Hospitals That Bought the Fakes Are Part of the Failure

• The steep discount was itself the warning sign
• The fake and expiry-altered stock was sold at steep discounts to over 90 hospitals and clinics [4].

• A genuine, time-sensitive cancer or ICU injection has little room for a deep discount. A price far below the market is a reason to check the seller, not a reason to buy.

• Nothing in the buying process forces a check

• Hospital purchase is usually decided by the lowest quote.
• There is no duty on the hospital to confirm that the supplier holds a valid sale licence, or to keep a record linking each batch to a licensed distributor.

• So an unlicensed farmhouse unit could reach 90+ institutions without one buyer stopping it [4].

• What should change

• Karnataka Drugs Control Department: make every hospital keep a purchase record showing the licensed distributor and batch for each consignment, and make the SIT's hospital list public so patients can ask what they were given [4].
• Uniform rules across states, as Mashelkar (2003) asked: a rule that binds only Karnataka just pushes the trade to a neighbouring state [7].
• Reporting upward: WHO runs a Global Surveillance and Monitoring System to which countries report substandard and falsified products [6]. Hospitals that spot a suspect batch should be required to report it, so one hospital's suspicion becomes a national alert.

12. The Honest Counter-View: Enforcement Has Actually Been Tightening

• The strongest argument on the other side
• Detected spurious drug cases fell from 424 in 2022-23 to 245 in 2024-25 [8].
• The risk-based inspection drive since December 2022 produced 694 enforcement actions out of 905 units inspected — a very high hit rate [3].

• The Kolkata seizure of ₹6.6 crore of fake anti-cancer and anti-diabetic drugs was a joint CDSCO–West Bengal operation, which shows Centre-State teamwork does work when it is switched on [1].

• What is genuinely right in that view — this is real tightening, not paperwork. A regulator that acts on three out of four units it visits is not an idle regulator [3].

• But a falling detection count is not proof of a falling problem
• Detections depend on how many samples were drawn and where. Fewer catches can mean fewer or weaker checks, not fewer fakes.
• Inspections cover licensed premises [3]. The Bidadi unit sat completely outside that universe [4], so no amount of inspecting licensed factories would ever have found it.
• Use both facts in an answer: enforcement inside the licensed system is improving, while the unlicensed system stays unmeasured.

13. Anchors for Answers

• Data: 47,012 samples tested — 13 spurious (0.02%) and 1,850 NSQ (3.16%) [5]
• Data: WHO — about 1 in 10 medical products in low- and middle-income countries is substandard or falsified; US$30.5 billion spent on them each year; based on 48,000 samples from 88 countries [6]
• Data: CDSCO sanctioned posts rose from 111 (2008) to 492 (January 2021) [5]
• Data: Detected spurious cases fell from 424 in 2022-23 to 245 in 2024-25 [8]
• Report/Committee: Mashelkar Committee, 2003 — too few trained staff, non-uniform enforcement across states, weak drug control infrastructure [7]
• Report/Committee: Parliamentary Standing Committee on Health, report on CDSCO tabled 8 May 2012 — 31 new drugs approved between January 2008 and October 2010 without trials on Indian patients; collusion between manufacturers, CDSCO officials and experts [7]
• Law/Case: Drugs and Cosmetics Act, 1940 and Rules, 1945 — definition of "spurious drug", up to 3 years imprisonment with fine [3]
• Comparison: WHO Global Surveillance and Monitoring System — member countries report substandard and falsified medical products to a common pool, turning one local find into a global alert [6]
• Scheme: Track-and-trace QR/barcode — compulsory for the top 300 brands from 1 August 2023; extended to vaccines, narcotics and anticancer drugs by July 2027 and antimicrobials by July 2028 [8]

14. Mains Relevance

• GS-II: Governance — Issues relating to development and management of Social Sector/Health; Government policies and interventions.
• GS-III: Science & technology; Indian economy — issues related to public health infrastructure, pharmaceutical regulation.
• Possible question stems: 1. Discuss the regulatory and enforcement challenges in curbing the circulation of spurious drugs in India. Suggest reforms to strengthen the pharmaceutical supply chain. (GS-II/III) 2. Drug regulation in India suffers from a Centre-State coordination deficit. Examine with reference to recent counterfeit drug rackets. (GS-II) 3. Evaluate the adequacy of penal provisions under the Drugs and Cosmetics Act, 1940 in deterring large-scale spurious drug trade. (GS-II)

15. Related Topics to Study Next

• Drugs (Control) Act & Essential Commodities Act — related drug-pricing/availability regulation.
• National Pharmaceutical Pricing Authority (NPPA) — pricing regulation intersecting with quality issues.
• Ayushman Bharat / public healthcare access — vulnerability of patients relying on subsidised drugs.
• India as "pharmacy of the world" — generics export reputation at stake from quality scandals.
• Track and Trace system for drugs — QR-code/barcode traceability reforms proposed by government.
• Concurrent List & Centre-State health administration — federal structure of health/drug regulation.
• Food Safety and Standards Authority of India (FSSAI) — comparative regulatory body model for another sector.
• WHO framework on Substandard and Falsified (SF) medical products — international benchmarking [S from earlier WHO reference].

16. Common Errors / Trap Areas

• Confusing CDSCO (central regulator, drug standards/licensing of new drugs, imports) with state drug controllers (day-to-day licensing/enforcement within states) — aspirants often assign all drug enforcement wrongly to the Centre.
• Mixing up "spurious" vs "substandard" (Not of Standard Quality) drugs — spurious implies deliberate misrepresentation/counterfeiting; substandard implies quality failure without intent to deceive; the Act distinguishes these.
• Assuming FSSAI regulates medicines — FSSAI governs food, not drugs; drugs fall under Drugs and Cosmetics Act/CDSCO.
• Wrong ministry attribution: it is Ministry of Health & Family Welfare, not Ministry of Chemicals & Fertilizers (which handles pharma pricing/production policy via Department of Pharmaceuticals) — the two ministries have overlapping but distinct roles.
• Underestimating penalty provisions — many assume harsher punishment exists; current law caps at 3 years imprisonment for basic spurious drug offences (higher penalties apply only for drugs causing grievous hurt/death under specific sections).